{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:02:03Z","timestamp":1780938123297,"version":"3.54.1"},"reference-count":328,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Non-Hodgkin lymphoma (NHL) encompasses a biologically diverse group of malignancies for which the integration of precision medicine has markedly reshaped therapeutic strategies. Recent advances in molecular profiling, target identification, and drug development have led to the introduction of highly selective agents capable of overcoming resistance mechanisms and improving outcomes in relapsed or refractory disease. This review highlights three targeted therapies\u2014pirtobrutinib, brentuximab vedotin, and belinostat\u2014and their evolving roles in modern NHL management. Pirtobrutinib, a next-generation, non-covalent Bruton tyrosine kinase (BTK) inhibitor, demonstrates preserved activity in patients previously treated with covalent BTK inhibitors (BTKi), addressing a critical unmet need in B-cell lymphomas. Brentuximab vedotin, an antibody\u2013drug conjugate targeting CD30, has significantly improved therapeutic precision by delivering cytotoxic agents directly to lymphoma cells and has become a central component of treatment for CD30-expressing NHL subtypes. Belinostat, a broad-spectrum histone deacetylase (HDAC) inhibitor, offers a mechanistically distinct epigenetic approach, particularly in peripheral T-cell lymphomas (PTCL), where conventional chemotherapy has limited efficacy. Together, these agents exemplify three complementary paradigms of precision oncology in NHL: kinase signaling inhibition, antigen-directed cytotoxic delivery, and epigenetic modulation. This review synthesizes current evidence, clinical trial data, and future perspectives regarding the integration of pirtobrutinib, brentuximab vedotin, and belinostat into evolving treatment paradigms. Cumulatively, these therapies illustrate both the progress and the ongoing challenges of biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic sequencing, and variability in evidence maturity across targeted strategies. While pirtobrutinib and brentuximab vedotin are supported by increasingly robust clinical evidence in selected lymphoma subtypes, the role of belinostat remains constrained by modest response rates and limited randomized data, underscoring the continued need for biomarker refinement and more precisely individualized therapeutic approaches in NHL precision medicine.<\/jats:p>","DOI":"10.3390\/jcm15124425","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:04:14Z","timestamp":1780913054000},"page":"4425","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody\u2013Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3902-2744","authenticated-orcid":false,"given":"Piotr","family":"Kawczak","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"B\u0105czek","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gda\u0144sk, 80-416 Gda\u0144sk, Poland"},{"name":"Department of Nursing and Medical Rescue, Institute of Health Sciences, Pomeranian University in S\u0142upsk, 76-200 S\u0142upsk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"ref_1","unstructured":"(2026, April 15). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1480."},{"key":"ref_2","unstructured":"(2026, April 15). NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas. National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1483."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/10428194.2023.2297939","article-title":"The 5th Edition of the World Health Organization Classification of Mature Lymphoid and Stromal Tumors\u2014An Overview and Update","volume":"65","author":"Attygalle","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","article-title":"Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture the Molecular and Biological Heterogeneity of the Disease","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/his.15323","article-title":"Closing the gap between biology and classification in splenic B-cell lymphomas","volume":"86","author":"Blombery","year":"2025","journal-title":"Histopathology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","article-title":"Diffuse large B-cell lymphoma: R-CHOP failure\u2014What to do?","volume":"2016","author":"Coiffier","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102042","DOI":"10.1016\/j.ctrv.2020.102042","article-title":"Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies","volume":"88","author":"Tun","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/EDBK_279043","article-title":"ADCs, BiTEs, CARs, and small molecules: A new era of targeted therapy in non-Hodgkin lymphoma","volume":"40","author":"Abramson","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1080\/10428194.2025.2599994","article-title":"Management of relapsed\/refractory diffuse large B-cell lymphoma in the era of novel agents and new approaches","volume":"67","author":"Gong","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","first-page":"CD013365","article-title":"Chimeric Antigen Receptor (CAR) T-Cell Therapy for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B-cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.14694\/EdBook_AM.2015.35.e449","article-title":"ABC, GCB, and double-hit diffuse large B-cell lymphoma: Does subtype make a difference in therapy selection?","volume":"35","author":"Nowakowski","year":"2015","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14740338.2020.1802424","article-title":"Safety Considerations with Targeted Therapy Drugs for B-Cell Non-Hodgkin Lymphoma","volume":"19","author":"Makita","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chaudhari, J., and Shah, N.N. (2025). Targeted therapies and immunotherapies for diffuse large B-cell lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17152517"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncoscience.633","article-title":"Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions","volume":"12","author":"Tiwari","year":"2025","journal-title":"Oncoscience"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2021.10.018","article-title":"Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds","volume":"524","author":"Cox","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/14656566.2021.1902988","article-title":"Novel synthetic drugs for the treatment of non-Hodgkin lymphoma","volume":"22","author":"Manji","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/joim.13423","article-title":"Towards precision medicine in lymphoid malignancies","volume":"292","author":"Campo","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e71873","DOI":"10.1002\/hsr2.71873","article-title":"Advancing the diagnosis of non-Hodgkin lymphoma through next-generation sequencing in developing countries: An evaluation of progress\u2014A narrative review","volume":"9","author":"Saeidnia","year":"2026","journal-title":"Health Sci. Rep."},{"key":"ref_27","first-page":"1339","article-title":"Characterization of tumor microenvironment and cell interaction patterns in testicular and diffuse large B-cell lymphomas","volume":"110","author":"Autio","year":"2025","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Dom\u00ednguez, D.J., Hontecillas-Prieto, L., Palaz\u00f3n-Carri\u00f3n, N., Jim\u00e9nez-Cortegana, C., S\u00e1nchez-Margalet, V., and de la Cruz-Merino, L. (2022). Tumor immune microenvironment in lymphoma: Focus on epigenetics. Cancers, 14.","DOI":"10.3390\/cancers14061469"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyro-sine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Moldovianu, A.-M., Stoia, R., Vasilica, M., Ursuleac, I., Badelita, S.N., Tomescu, A.A., Pre-da, O.D., Bardas, A., Cirstea, M., and Coriu, D. (2023). Real-world clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Medicina, 59.","DOI":"10.3390\/medicina59020324"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","article-title":"FDA approval summary: Pirtobrutinib for relapsed or refrac-tory mantle cell lymphoma","volume":"30","author":"Telaraja","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ejh.70036","article-title":"Bruton tyrosine kinase inhibitors in mantle cell lymphoma: What are the current options?","volume":"115","author":"Caserta","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin in relapsed or refractory systemic anaplastic large-cell lymphoma","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_36","first-page":"228","article-title":"Erratum in: Department of Error: Brentuximab vedotin with chemotherapy for CD30-positive PTCL (ECHELON-2)","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14712598.2017.1334053","article-title":"Targeting non-Hodgkin lymphoma with blinatumomab","volume":"17","author":"Sanders","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminhematol.2016.05.011","article-title":"Novel agents in Hodgkin lymphoma","volume":"53","author":"Younes","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-025-01841-z","article-title":"Advances in epigenetic treatment of adult T-cell leukemia\/lymphoma","volume":"17","author":"Letafati","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"Horwitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lam, H.P.J., Amin, F., Arulogun, S.O., and Gleeson, M. (2025). Nodal peripheral T-cell lymphoma: Therapeutic challenges and future perspectives. Cancers, 17.","DOI":"10.3390\/cancers17071134"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1080\/10428194.2025.2545927","article-title":"Relapsed and refractory peripheral T-cell lymphoma: Treatment, challenges and future perspectives","volume":"66","author":"Meeuwes","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/j.semnuclmed.2022.10.003","article-title":"Molecular imaging of lymphoma: Future directions and perspectives","volume":"53","author":"Pomykala","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: Principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/13696998.2026.2651055","article-title":"Cost-efficiency modeling of conversion to biosimilar rituximab-based R-CHOP in diffuse large B-cell lymphoma in Medicare","volume":"29","author":"Roth","year":"2026","journal-title":"J. Med. Econ."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12272-025-01546-0","article-title":"BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies","volume":"48","author":"Kim","year":"2025","journal-title":"Arch. Pharm. Res."},{"key":"ref_50","first-page":"162","article-title":"Pirtobrutinib for the treatment of B-cell malignancies: Recent developments","volume":"22","author":"Schmidt","year":"2024","journal-title":"Hematol. Blood Transfus."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_55","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Mouhssine, S., Maher, N., Matti, B.F., Alwan, A.F., and Gaidano, G. (2024). Targeting BTK in B cell malignancies: From mode of action to resistance mechanisms. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063234"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","article-title":"Dermatological Toxicities of Bruton\u2019s Tyrosine Kinase Inhibitors","volume":"21","author":"Sibaud","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Robak, T., Witkowska, M., and Smolewski, P. (2022). The role of Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers, 14.","DOI":"10.3390\/cancers14030771"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_63","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20406207221101697","DOI":"10.1177\/20406207221101697","article-title":"The potential of pirtobrutinib in multiple B-cell malignancies","volume":"13","author":"Jensen","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: First approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/10781552231216886","article-title":"Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed\/refractory mantle cell lymphoma","volume":"30","author":"Davis","year":"2024","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.2174\/0109298673251030231004052822","article-title":"Pirtobrutinib: First non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults","volume":"31","author":"De","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_68","unstructured":"(2026, April 06). Pirtobrutinib is an Orally Active, Highly Selective and non-Covalent BTK Inhibitor. Network of Cancer Research. Available online: https:\/\/www.cancer-research-network.com\/2021\/05\/06\/pirtobrutinib-is-an-orally-active-highly-selective-and-non-covalent-btk-inhibitor\/."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1080\/14796694.2025.2567834","article-title":"Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"21","author":"Ibrahim","year":"2025","journal-title":"Future Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Molica, S., and Allsup, D. (2025). Pirtobrutinib in chronic lymphocytic leukemia: Navigating resistance and the personalisation of BTK-targeted therapy. Cancers, 17.","DOI":"10.20944\/preprints202508.1373.v1"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e7289","DOI":"10.1002\/cam4.7289","article-title":"Outcomes of pirtobrutinib for relapsed\/refractory mantle cell lymphoma in a compassionate use program in Europe","volume":"13","author":"Aydilek","year":"2024","journal-title":"Cancer Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.1182\/bloodadvances.2024014975","article-title":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in relapsed\/refractory follicular lymphoma: Phase 1\/2 BRUIN study","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/bloodadvances.2025017489","article-title":"Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in relapsed\/refractory marginal zone lymphoma: Phase 1\/2 BRUIN study","volume":"10","author":"Patel","year":"2026","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/hematology.2022000345","article-title":"Treatment of Richter\u2019s syndrome","volume":"2022","author":"Thompson","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11899-025-00765-y","article-title":"The evolving therapeutic landscape of Richter transformation","volume":"20","author":"Le","year":"2025","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2217\/fon-2022-0976","article-title":"BRUIN MCL-321: Phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor-naive mantle cell lymphoma","volume":"18","author":"Eyre","year":"2022","journal-title":"Future Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s12325-024-02822-z","article-title":"Matching-adjusted indirect comparison of brexucabtagene autoleucel (ZUMA-2) and pirtobrutinib (BRUIN) in patients with relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor","volume":"41","author":"Salles","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/bloodadvances.2025016006","article-title":"Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia","volume":"9","author":"Yoon","year":"2025","journal-title":"Blood Adv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11864-023-01112-0","article-title":"Current treatment options in relapsed and refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: A review","volume":"24","author":"Islam","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/01.HS9.0000850308.96349.64","article-title":"PB1864: BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib vs investigator\u2019s choice of idelalisib + rituximab or bendamustine + rituximab in BTKi pretreated CLL\/SLL (trial in progress)","volume":"6","author":"Sharman","year":"2022","journal-title":"Hemasphere"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41408-025-01382-x","article-title":"Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression","volume":"15","author":"Tantawy","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1200\/JCO-25-02477","article-title":"Pirtobrutinib versus ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"44","author":"Woyach","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Xu, J., Lin, J., Gan, H., He, Q., Wang, W., and Liu, Y. (2025). Investigation of the mechanism of hypertension caused by BTKi in the treatment of hematologic diseases. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1585061"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41375-024-02334-3","article-title":"Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation","volume":"38","author":"Gambril","year":"2024","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: A review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/bjh.70334","article-title":"A Comprehensive Analysis of Pirtobrutinib in Chinese Patients with Chronic Lymphocytic Leukaemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Results from the Phase 3 Study BRUIN CLL-321","volume":"208","author":"Yi","year":"2026","journal-title":"Br. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Mehra, S., Nicholls, M., and Taylor, J. (2024). The evolving role of Bruton\u2019s tyrosine kinase inhibitors in B cell lymphomas. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147516"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3960\/jslrt.25028","article-title":"BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL","volume":"65","author":"Kojima","year":"2025","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/14656566.2024.2390121","article-title":"Evaluation of infectious morbidity due to BTK inhibitors in indolent B-cell lymphomas: Latest research findings and systematic analysis","volume":"25","author":"Dasanu","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1080\/03007995.2025.2607542","article-title":"Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1\/2 study: Final analysis","volume":"41","author":"Coombs","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_95","unstructured":"(2026, April 15). Study Evaluating Pirtobrutinib in Combination with Rituximab and Venetoclax in Participants with Previously Untreated Mantle Cell Lymphoma (GATE1). Identifier: NCT06522386. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06522386."},{"key":"ref_96","unstructured":"(2026, April 15). Study of Pirtobrutinib in Combination with Venetoclax in Participants with Relapsed\/Refractory Mantle Cell Lymphoma. Identifier: NCT05529069. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05529069."},{"key":"ref_97","unstructured":"(2026, April 15). Study of Pirtobrutinib in Combination with Rituximab in Participants with Previously Untreated Mantle Cell Lymphoma. Identifier: NCT06263491. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06263491."},{"key":"ref_98","unstructured":"(2026, April 15). Study of Pirtobrutinib in Combination with Glofitamab in Participants with Relapsed\/Refractory Mantle Cell Lymphoma. Identifier: NCT06252675. ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06252675."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood.2024026919","article-title":"TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40364-022-00357-5","article-title":"Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_101","first-page":"E966","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Kohrt","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Jiang, Q., Peng, Y., Herling, C.D., and Herling, M. (2024). The immunomodulatory mechanisms of BTK inhibition in CLL and beyond. Cancers, 16.","DOI":"10.3390\/cancers16213574"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski, K., and Pu\u0142a, B. (2024). A review of resistance mechanisms to Bruton\u2019s kinase inhibitors in chronic lymphocytic leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105246"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/17474086.2023.2271170","article-title":"Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy","volume":"16","author":"Molica","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Montoya, S., and Thompson, M.C. (2023). Non-covalent Bruton\u2019s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers, 15.","DOI":"10.3390\/cancers15143648"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: Second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ejh.70160","article-title":"Pirtobrutinib at the crossroads: Shaping its future role in chronic lymphocytic leukemia (CLL) care","volume":"117","author":"Molica","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_110","unstructured":"(2026, April 15). JAYPIRCA (pirtobrutinib) Prescribing Information. Available online: https:\/\/pi.lilly.com\/us\/jaypirca-uspi.pdf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/17474086.2024.2389993","article-title":"Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"17","author":"Wang","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: Analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ajh.70107","article-title":"CD30 as a target molecule in the diagnosis and therapy of lymphomas","volume":"101","author":"Stein","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions","volume":"7","author":"Pileri","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3960\/jslrt.25048","article-title":"Prognostic and immunomodulatory roles of CD30 in diffuse large B-cell lymphoma: A cell-of-origin- and microenvironment-dependent paradigm","volume":"65","author":"Tanaka","year":"2025","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Dhimolea","year":"2012","journal-title":"MAbs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1517\/17425247.2.5.873","article-title":"Antibody-Cytotoxic Agent Conjugates for Cancer Therapy","volume":"2","author":"Chen","year":"2005","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40259-013-0068-8","article-title":"CD30 as a Therapeutic Target for Lymphoma","volume":"28","author":"Schirrmann","year":"2014","journal-title":"BioDrugs"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"104979","DOI":"10.1016\/j.critrevonc.2025.104979","article-title":"Bystander effect in antibody\u2013drug conjugates: Navigating the fine line in tumor heterogeneity","volume":"216","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Shi, R., Jia, L., Lv, Z., and Cui, J. (2025). Another power of antibody\u2013drug conjugates: Immunomodulatory effect and clinical applications. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1632705"},{"key":"ref_124","first-page":"1","article-title":"New therapies in T-cell lymphoma","volume":"4","author":"Collins","year":"2014","journal-title":"Lymphoma Chronic Lymphocytic Leuk."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2146\/ajhp110608","article-title":"Brentuximab vedotin: An anti-CD30 antibody\u2013drug conjugate","volume":"70","author":"Bradley","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","article-title":"Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin\u2019s lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2147\/DDDT.S82007","article-title":"Brentuximab vedotin for relapsed or refractory Hodgkin\u2019s lymphoma","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: A review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.clml.2026.02.003","article-title":"SOHO state of the art updates and next questions: Optimizing frontline treatment for peripheral T-cell lymphoma","volume":"26","author":"Akkad","year":"2026","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/bloodadvances.2025018042","article-title":"Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy","volume":"10","author":"Saleh","year":"2026","journal-title":"Blood Adv."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Kim, T.Y., Kim, T.J., Han, E.J., Min, G.J., Cho, S.G., and Jeon, Y. (2025). Impact of KMT2A rearrangement on peripheral T-cell lymphoma, not otherwise specified, and angioimmunoblastic T-cell lymphoma. Biomedicines, 13.","DOI":"10.20944\/preprints202509.0562.v1"},{"key":"ref_134","first-page":"68","article-title":"Haematological Cancer: Brentuximab Effective in Untreated Hodgkin Lymphoma","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/ejh.70060","article-title":"Brentuximab vedotin with adriamycin, vinblastine, and dacarbazine for patients aged 18\u201359 years with untreated advanced stage classical Hodgkin lymphoma: The largest real-life series from Southern Italy cancer centers","volume":"116","author":"Picardi","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin\u2019s Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_137","first-page":"532","article-title":"Erratum in: Department of Error: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4274\/tjh.galenos.2026.35403","article-title":"Allogeneic hematopoietic cell transplantation for relapsed\/refractory Hodgkin lymphoma: A multicenter real-world experience","volume":"43","author":"Koyun","year":"2026","journal-title":"Turk. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","article-title":"Patient-Reported Quality of Life in Patients with Relapsed\/Refractory Cutaneous T-Cell Lymphoma: Results from the Randomised Phase III ALCANZA Study","volume":"133","author":"Dummer","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14796694.2025.2513219","article-title":"Plain language summary of the ECHELON-3 study: Brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma","volume":"21","author":"Bartlett","year":"2025","journal-title":"Future Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ajh.70229","article-title":"2026 update on the management of diffuse large B-cell lymphoma","volume":"101","author":"Chong","year":"2026","journal-title":"Am. J. Hematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: A multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Massaro, F., Meuleman, N., Bron, D., Vercruyssen, M., and Maerevoet, M. (2022). Brentuximab vedotin and pembrolizumab combination in patients with relapsed\/refractory Hodgkin lymphoma: A single-centre retrospective analysis. Cancers, 14.","DOI":"10.3390\/cancers14040982"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2018.05.40","article-title":"Is There a Place for the Combination of Brentuximab Vedotin and Bendamustine in Treatment of Patients with Relapsed\/Refractory Hodgkin Lymphoma?","volume":"6","author":"Chen","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/bloodadvances.2024015787","article-title":"Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: A LYSA phase 2 study","volume":"9","author":"Tournilhac","year":"2025","journal-title":"Blood Adv."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.2147\/OTT.S193951","article-title":"Safety and efficacy of brentuximab vedotin in the treatment of classic Hodgkin lymphoma","volume":"13","author":"Makita","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s44313-025-00097-z","article-title":"Brentuximab vedotin combined with cisplatin, cytarabine, and dexamethasone treatment in transplant-eligible Korean patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"60","author":"Yi","year":"2025","journal-title":"Blood Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e70143","DOI":"10.1002\/hon.70143","article-title":"Randomized phase II study of brentuximab vedotin with high-dose chemotherapy in CD30-positive lymphoma","volume":"43","author":"Rausch","year":"2025","journal-title":"Hematol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"104499","DOI":"10.1016\/j.critrevonc.2024.104499","article-title":"Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma","volume":"204","author":"Abramson","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1470-2045(21)00138-8","article-title":"Relapsed or Refractory Classical Hodgkin Lymphoma: Which Immunotherapy, and When?","volume":"22","author":"Vassilakopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14796694.2025.2599082","article-title":"Nivolumab plus brentuximab vedotin for relapsed\/refractory diffuse large B-cell lymphoma","volume":"22","author":"Johnson","year":"2026","journal-title":"Future Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-Hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Dumitru, A.V., \u021a\u0103poi, D.A., Halcu, G., Munteanu, O., Dumitrascu, D.-I., Ceau\u0219u, M.C., and Gheorghi\u0219an-G\u0103l\u0103\u021beanu, A.-A. (2023). The polyvalent role of CD30 for cancer diagnosis and treatment. Cells, 12.","DOI":"10.3390\/cells12131783"},{"key":"ref_159","first-page":"e103554","article-title":"Brentuximab-induced peripheral neuropathy in the setting of radiation-induced brachial plexopathy","volume":"18","author":"Gu","year":"2026","journal-title":"Cureus"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"102932","DOI":"10.1016\/j.jgo.2026.102932","article-title":"Brentuximab vedotin and dose-attenuated chemoimmunotherapy for patients 75 years and older with diffuse large B-cell lymphoma with analysis of outcomes by frailty","volume":"17","author":"Reagan","year":"2026","journal-title":"J. Geriatr. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/cas.14933","article-title":"Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review","volume":"112","author":"Yasuda","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_162","first-page":"293","article-title":"Current treatment of peripheral T-cell lymphoma","volume":"36","author":"Stuver","year":"2022","journal-title":"Oncology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/14796694.2024.2357537","article-title":"End points in clinical trials in diffuse large B-cell lymphoma: Time for more dialogue?","volume":"20","author":"Degtyarev","year":"2024","journal-title":"Future Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.11.009","article-title":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review","volume":"109","author":"Berger","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Yang, Y., Liu, S.-R., Wang, L., Zhang, R., and Xie, J. (2025). Frontline brentuximab vedotin-based therapy for newly diagnosed classical Hodgkin lymphoma: A meta-analysis of randomized controlled trials. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1636923"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/hematology.2024000668","article-title":"When should we use it? The role of brentuximab vedotin in 2024","volume":"2024","author":"Advani","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_167","first-page":"2596423","article-title":"Novel brentuximab vedotin combination therapies show promising activity in highly refractory CD30+ non-Hodgkin lymphoma: A case series and review of the literature","volume":"2016","author":"Delacruz","year":"2016","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41409-025-02557-7","article-title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: A systematic review and meta-analysis","volume":"60","author":"Sureda","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Massa, H., Massaro, F., and Maerevoet, M. (2025). Combination of brentuximab vedotin and pembrolizumab as salvage treatment before autologous stem cell transplantation and maintenance in patients with relapsed\/refractory Hodgkin lymphoma. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020252"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"108192","DOI":"10.1016\/j.isci.2023.108192","article-title":"Advances and challenges of immunotherapies in NK\/T cell lymphomas","volume":"26","author":"He","year":"2023","journal-title":"iScience"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17474086.2025.2492936","article-title":"Advancements in targeting CD30 for lymphoma therapy: A historical perspective and future directions","volume":"18","author":"Zhang","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e71695","DOI":"10.1002\/cam4.71695","article-title":"Survival trends and prognostic modeling in ALK-positive anaplastic large cell lymphoma: A population-based study in the brentuximab vedotin era","volume":"15","author":"Zhang","year":"2026","journal-title":"Cancer Med."},{"key":"ref_174","unstructured":"(2026, April 15). ADCETRIS (Brentuximab Vedotin) Prescribing Information. Seagen Inc.. Available online: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=20629."},{"key":"ref_175","unstructured":"(2026, April 15). Brentuximab Vedotin (Adcetris) Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125388_s056s078lbl.pdf."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1158\/1078-0432.CCR-11-3144","article-title":"Romidepsin for cutaneous T-cell lymphoma","volume":"18","author":"Prince","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: Potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell Biochem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e230224227378","DOI":"10.2174\/0115701638286941240217102948","article-title":"Discovery and development of HDAC inhibitors: Approaches for the treatment of cancer\u2014A mini-review","volume":"21","author":"Patel","year":"2024","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7150\/ijms.30154","article-title":"Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas","volume":"16","author":"Zhang","year":"2019","journal-title":"Int. J. Med. Sci."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1568026619666190122144949","article-title":"Zinc-dependent deacetylase (HDAC) inhibitors with different zinc binding groups","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.18632\/oncotarget.2289","article-title":"HDAC inhibitors and immunotherapy: A double-edged sword?","volume":"5","author":"Kroesen","year":"2014","journal-title":"Oncotarget"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/13543784.2016.1164140","article-title":"An overview of investigational histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin\u2019s lymphoma","volume":"25","author":"Apuri","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/ajhp\/zxz202","article-title":"Current targeted therapies in lymphomas","volume":"76","author":"Chung","year":"2019","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin. Epigenet."},{"key":"ref_191","unstructured":"(2026, April 06). Beleodaq\u00ae (Belinostat) for Injection. Available online: https:\/\/beleodaq.com\/hcp\/about."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2146\/news140056","article-title":"Belinostat approved for use in treating rare lymphoma","volume":"71","author":"Thompson","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.2217\/fon.15.62","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"11","author":"Rashidi","year":"2015","journal-title":"Future Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.24.00100","article-title":"US Food and Drug Administration\u2019s directive to deal with delayed confirmatory trials: Lessons from pralatrexate and belinostat for T-cell lymphoma","volume":"42","author":"Cliff","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CCO.0000000000000469","article-title":"New perspectives in the therapeutic approach of peripheral T-cell lymphoma","volume":"30","author":"Gisselbrecht","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14712598.2019.1572746","article-title":"Development of new agents for peripheral T-cell lymphoma","volume":"19","author":"Ito","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"102793","DOI":"10.1016\/j.ctrv.2024.102793","article-title":"Peripheral T-cell lymphoma: From biology to practice to the future","volume":"129","author":"Ma","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 phar-macokinetic and pharmacodynamic study of the histone deacetylase inhibi-tor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1080\/10428194.2020.1753044","article-title":"Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"61","author":"Sawas","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.09.018","article-title":"Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer","volume":"329","author":"Diyabalanage","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/CMAR.S85351","article-title":"New developments in the treatment of peripheral T-cell lymphoma\u2014Role of belinostat","volume":"7","author":"Reimer","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10637-014-0194-2","article-title":"A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia","volume":"33","author":"Odenike","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11899-010-0067-5","article-title":"The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas","volume":"6","author":"Horwitz","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/10428194.2019.1691194","article-title":"Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Irimia, R., and Piccaluga, P.P. (2024). Histone deacetylase inhibitors for peripheral T-cell lymphomas. Cancers, 16.","DOI":"10.20944\/preprints202408.0744.v1"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjh.16160","article-title":"Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma","volume":"188","author":"Passero","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"115212","DOI":"10.1016\/j.biopha.2023.115212","article-title":"Anticancer Clinical Efficiency and Stochastic Mechanisms of Belinostat","volume":"165","author":"Bakrim","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2021.01.004","article-title":"Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"101","author":"Jimura","year":"2021","journal-title":"J. Dermatol. Sci."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/bjh.70188","article-title":"Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines","volume":"207","author":"Hu","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.2147\/CMAR.S149241","article-title":"Hematologic toxicity is rare in relapsed patients treated with belinostat: A systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas","volume":"10","author":"Allen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"35880","DOI":"10.1038\/s41598-025-19717-w","article-title":"Adverse drug reaction profiles of histone deacetylase inhibitors","volume":"15","author":"Begum","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/ph3092751","article-title":"Clinical toxicities of histone deacetylase inhibitors","volume":"3","author":"Subramanian","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/14656566.2021.1882997","article-title":"Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma","volume":"22","author":"Smolewski","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-06-1715","article-title":"HDAC inhibitors and cardiac safety","volume":"13","author":"Molife","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e70077","DOI":"10.1111\/cpr.70077","article-title":"Role of histone deacetylase and inhibitors in cardiovascular diseases","volume":"58","author":"Zhang","year":"2025","journal-title":"Cell Prolif."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00280-010-1419-5","article-title":"Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor belinostat (PXD101)","volume":"67","author":"Steele","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.625","article-title":"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer","volume":"56","author":"Goey","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.phrs.2016.01.002","article-title":"UGT genotyping in belinostat dosing","volume":"105","author":"Goey","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.gendis.2018.06.003","article-title":"Epigenetic mechanisms as a new approach in cancer treatment: An updated review","volume":"5","author":"Fardi","year":"2018","journal-title":"Genes Dis."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2174\/0109298665398122250929045705","article-title":"PLEKHG7 expression: A biomarker for prognosis and targeted therapy in diffuse large B-cell lymphoma","volume":"32","author":"Lyu","year":"2025","journal-title":"Protein Pept. Lett."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1517\/13543784.2011.629604","article-title":"Belinostat: Clinical applications in solid tumors and lymphoma","volume":"20","author":"Molife","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.4103\/jcrt.jcrt_1213_22","article-title":"Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated","volume":"20","author":"Atalay","year":"2024","journal-title":"J. Cancer Res. Ther."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41375-024-02483-5","article-title":"Surrogate endpoints in mature B-cell neoplasms\u2014Meaningful or misleading?","volume":"39","author":"Simon","year":"2025","journal-title":"Leukemia"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"4987103","DOI":"10.1155\/2018\/4987103","article-title":"Epigenetic biomarkers in cancer","volume":"2018","author":"Cheng","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1182\/bloodadvances.2020002297","article-title":"Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy","volume":"4","author":"Islam","year":"2020","journal-title":"Blood Adv."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Da\u015bko, M., de Pascual-Teresa, B., Ort\u00edn, I., and Ramos, A. (2022). HDAC inhibitors: Innovative strategies for their design and applications. Molecules, 27.","DOI":"10.3390\/molecules27030715"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","article-title":"Targeting epigenetics in cancer","volume":"58","author":"Bennett","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/his.15376","article-title":"Advances in peripheral T-cell lymphomas: Pathogenesis, genetic landscapes and emerging therapeutic targets","volume":"86","author":"Pichler","year":"2024","journal-title":"Histopathology"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"101416","DOI":"10.1016\/j.xcrm.2024.101416","article-title":"Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_238","doi-asserted-by":"crossref","unstructured":"Harrop, S., Abeyakoon, C., Van Der Weyden, C., and Prince, H.M. (2021). Targeted Approaches to T-Cell Lymphoma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060481"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jjco\/hyaf158","article-title":"Recent Advances and Future Perspectives in Frontline Treatment of Peripheral T-Cell Lymphoma","volume":"56","author":"Shirouchi","year":"2026","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Hawash, M. (2025). Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy. Cells, 14.","DOI":"10.3390\/cells14241997"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/hematology.2025000722","article-title":"Emerging Immunotherapy Advances for Non-Hodgkin Lymphomas: Engaging T Cells in the Fight","volume":"2025","author":"Rojek","year":"2025","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2012.48.3883","article-title":"Strategies for relapsed peripheral T-cell lymphoma: The tail that wags the curve","volume":"31","author":"Lunning","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_243","unstructured":"(2026, April 15). Belinostat (Beleodaq) Prescribing Information. U.S. Food and Drug Administration, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11684-024-1058-6","article-title":"Disparities in 36 Cancers across 185 Countries: Secondary Analysis of Global Cancer Statistics","volume":"18","author":"Li","year":"2024","journal-title":"Front. Med."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00292-023-01247-9","article-title":"The 2022 Classifications of Lymphoid Neoplasms: Keynote","volume":"44","author":"Campo","year":"2023","journal-title":"Pathologie"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2024025482","article-title":"How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-017-0448-2","article-title":"Current treatment of chronic lymphocytic leukemia","volume":"18","author":"Jamroziak","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/1078-0432.CCR-23-0409","article-title":"New means and challenges in the targeting of BTK","volume":"30","author":"Nawaratne","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"e70188","DOI":"10.1002\/hon.70188","article-title":"Genetic and transcriptomic profiles identify potential therapeutic targets of concurrent follicular and diffuse large B-cell lymphoma and transformed follicular lymphoma","volume":"44","author":"Sun","year":"2026","journal-title":"Hematol. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12964-025-02438-y","article-title":"Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: A single-center cohort study","volume":"23","author":"Liang","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Jean-Louis, G., and Cherng, H.J. (2025). Measurable residual disease testing during treatment with bispecific antibodies for lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17071153"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO-25-00668","article-title":"Five-year follow-up analysis of ZUMA-5: Axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"43","author":"Neelapu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.23.02470","article-title":"Glofitamab in relapsed\/refractory mantle cell lymphoma: Results from a phase I\/II study","volume":"43","author":"Phillips","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41375-026-02942-1","article-title":"Evolving therapeutic strategies in mantle cell lymphoma: Advancements and future directions","volume":"40","author":"Tavarozzi","year":"2026","journal-title":"Leukemia"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-026-01276-6","article-title":"The impact of AI on modern oncology from early detection to personalized cancer treatment","volume":"10","author":"Li","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41419-026-08593-5","article-title":"Dual targeting of PI3K\u03b4 and PPAR\u03b1 enhances antitumor activity via FoxO1 activation in follicular lymphoma","volume":"17","author":"Wang","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12325-021-01943-z","article-title":"The short-term efficacy and safety of brentuximab vedotin plus cyclophosphamide, epirubicin and prednisone in untreated PTCL: A real-world, retrospective study","volume":"39","author":"Feng","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.2023023108","article-title":"Toward a Cure for Classical Hodgkin Lymphoma without Chemotherapy","volume":"143","author":"Lynch","year":"2024","journal-title":"Blood"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"156098","DOI":"10.1016\/j.prp.2025.156098","article-title":"Challenges of CD30 expression and its impact on targeted treatment responses in non-Hodgkin lymphoma: New perspectives for evaluation and validation","volume":"272","author":"Shi","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.2021011572","article-title":"Brentuximab Vedotin: Frontline Help in ALCL","volume":"137","author":"Burke","year":"2021","journal-title":"Blood"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155216634178","article-title":"Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"23","author":"Campbell","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12185-026-04197-z","article-title":"Recent progress in T-cell malignancies including adult T-cell leukemia-lymphoma","volume":"123","author":"Nosaka","year":"2026","journal-title":"Int. J. Hematol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cac2.12374","article-title":"Crosstalk between metabolic reprogramming and epigenetics in cancer: Updates on mechanisms and therapeutic opportunities","volume":"42","author":"Ge","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas","volume":"35","author":"Wang","year":"2021","journal-title":"Leukemia"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.18724","article-title":"How I treat refractory\/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells","volume":"201","author":"Nagler","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Zhou, X., Tu, S., Wang, C., Huang, R., Deng, L., Song, C., Yue, C., He, Y., Yang, J., and Liang, Z. (2020). Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.564099"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-24-2267","article-title":"Facts and hopes: CAR T-cell therapy and immune contexture in non-Hodgkin lymphoma","volume":"31","author":"Hijazi","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Wang, C., Guo, Y., Han, F., Zhang, Y., Liu, C., Wu, Z., Tong, C., Yang, Q., Lu, Y., and Zhong, Y. (2026). Demethylation-primed tandem CD19\/CD20 CAR T cells in relapsed\/refractory B-cell lymphoma: A phase I\/II trial. Nat. Commun., Online Ahead of Print.","DOI":"10.1038\/s41467-026-72040-4"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11894-025-01028-9","article-title":"CD19 CAR-T cell therapy for relapsed or refractory nodal and gastrointestinal follicular lymphoma: Current advances and future perspectives","volume":"27","author":"Watanabe","year":"2025","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","article-title":"Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies","volume":"22","author":"Ruella","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Tang, W., and Yu, S. (2026). Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1792910"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"314","DOI":"10.34172\/apb.2024.034","article-title":"The art of bioimmunogenomics (BIGs) 5.0 in CAR-T cell therapy for lymphoma management","volume":"14","author":"Anurogo","year":"2024","journal-title":"Adv. Pharm. Bull."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40364-026-00910-6","article-title":"A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends","volume":"14","author":"Lai","year":"2026","journal-title":"Biomark. Res."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"20406223231215701","DOI":"10.1177\/20406223231215701","article-title":"Bispecific T cell engagers targeting CD20\/CD3 in B-cell lymphoma: Latest updates from 2023 EHA annual meeting","volume":"14","author":"Jin","year":"2023","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1080\/10428194.2025.2504719","article-title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma","volume":"66","author":"Dandamudi","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and tri-specific antibodies in non-Hodgkin lymphoma: Current data and perspectives","volume":"14","author":"Dulery","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/14712598.2024.2404079","article-title":"Mosunetuzumab for the treatment of follicular lymphoma","volume":"24","author":"Labanca","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood.2025028863","article-title":"Preclinical advances in glofitamab combinations: A new frontier for non-Hodgkin lymphoma","volume":"146","author":"Sam","year":"2025","journal-title":"Blood"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"115012","DOI":"10.1016\/j.intimp.2025.115012","article-title":"Targeting epigenetic reprogramming in DLBCL and its interaction with the tumor microenvironment for novel therapeutic approaches","volume":"161","author":"Zhou","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-025-01673-7","article-title":"Circulating tumor DNA in lymphoma: Technologies and applications","volume":"18","author":"Fu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ccell.2025.03.020","article-title":"AI-driven biomarkers for antibody-drug conjugates","volume":"43","author":"Loi","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: The convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat. Med."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat. Med."},{"key":"ref_297","doi-asserted-by":"crossref","unstructured":"Popescu, D.C., and G\u0103man, M.A. (2025). Artificial intelligence for risk stratification in diffuse large B-cell lymphoma: A systematic review of classification models and predictive performances. Med. Sci., 13.","DOI":"10.3390\/medsci13040280"},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12943-023-01904-w","article-title":"Therapeutic challenges in peripheral T-cell lymphoma","volume":"23","author":"Luan","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17474086.2017.1303374","article-title":"Targeting indolent non-Hodgkin lymphoma","volume":"10","author":"Leslie","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: A phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2023.2264430","article-title":"Novel treatment for mantle cell lymphoma\u2014Impact of BTK inhibitors and beyond","volume":"65","author":"Gribbin","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_303","doi-asserted-by":"crossref","unstructured":"Chu, Y., Liu, Y., Fang, X., Jiang, Y., Ding, M., Ge, X., Yuan, D., Lu, K., Li, P., and Li, Y. (2023). The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1059914"},{"key":"ref_304","first-page":"1866","article-title":"Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: A matching-adjusted indirect comparison","volume":"109","author":"Jen","year":"2024","journal-title":"Haematologica"},{"key":"ref_305","first-page":"100","article-title":"Noncovalent BTK inhibitors in B-cell lymphoma","volume":"21","author":"Coombs","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ejh.14401","article-title":"Relapsed\/refractory follicular lymphoma: Current advances and emerging perspectives","volume":"114","author":"Martino","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-026-04165-7","article-title":"Novel agents and therapeutic advances in T cell lymphoma","volume":"123","author":"Shirouchi","year":"2026","journal-title":"Int. J. Hematol."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Akkad, N., Huen, A., and Iyer, S.P. (2026). Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: What\u2019s new for investigational agents?. Expert Opin. Investig. Drugs, Online Ahead of Print.","DOI":"10.1080\/13543784.2026.2660920"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood.2023020779","article-title":"DLBCL: Who is high risk and how should treatment be optimized?","volume":"144","author":"Nowakowski","year":"2024","journal-title":"Blood"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: A landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"e009611","DOI":"10.1136\/jitc-2024-009611","article-title":"CAR-T cell therapy in developing countries: How long should we wait?","volume":"12","author":"Gautam","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0b013e31820c0b0f","article-title":"Cancer in resource-limited settings","volume":"56","author":"Krown","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/CCO.0000000000000966","article-title":"Update on bi-specific monoclonal antibodies for blood cancers","volume":"35","author":"Shouse","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2017.1329293","article-title":"Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: Chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development","volume":"12","author":"Kubuschok","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: A perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy Plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine Plus Rituximab versus CHOP Plus Rituximab as First-Line Treatment for Patients with Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 Non-Inferiority Trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized Trial of Bendamustine-Rituximab or R-CHOP\/R-CVP in First-Line Treatment of Indolent NHL or MCL: The BRIGHT Study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab Plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-MIND): A Multicentre, Prospective, Single-Arm, Phase 2 Study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in Relapsed\/Refractory Large B-Cell Lymphoma: 2-Year Follow-Up from the Pivotal EPCORE NHL-1 Trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1\u20132 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4425\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:41:26Z","timestamp":1780936886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":328,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124425"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124425","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}